Making treatment guideline recommendations in chronic kidney disease and type 2 diabetes more accessible to primary care providers in the United States
Related Posts
Heerspink HJL, Neuen BL, Agarwal R, Cherney DZI, Lam CSP, Tuttle KR, Wanner C, Sarafidis P, Chertow GM, Friede T, Barratt J, Floege J, Chew-Wong[...]
Abdelnour L, Geara A, Kamal F. Mechanisms Behind the Disease: Understanding the Role of APRIL in IgAN Pathogenesis: A Podcast. Adv Ther. 2026 Nov 13.[...]
Naim MAAZ, Thomas F, Streja E, Davis RL, Kalantar-Zadeh K, Sumida K, Kovesdy CP. Cardiovascular Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies in Patients with CKD. Kidney[...]